TY -的T1接种肺炎球菌疫苗摩根富林明欧洲ean Respiratory Journal JO - Eur Respir J SP - 982 LP - 983 DO - 10.1183/09031936.05.00119705 VL - 26 IS - 6 AU - de Roux, A. AU - Lode, H. Y1 - 2005/12/01 UR - //www.qdcxjkg.com/content/26/6/982.abstract N2 - It has been some time now since Austrian et al. 1 performed a vaccination trial evaluating the effectiveness of a 15-valent pneumococcal polysaccharide vaccine (PPV) in South African gold miners. The receipt of this vaccine was associated with a reduction in the risk of pneumococcal bacteraemia and a >50% risk reduction of any radiographically confirmed cases of pneumonia 1. However, since the 23-valent PPV has been licensed it has been the subject of numerous debates, studies and controversies. Moreover, the aggregate financial and administrative cost of providing pneumococcal vaccination to all patients at risk is substantial. Nevertheless, pneumococcal vaccination is almost uniformly recommended in Europe for adults who are at high risk from pneumococcal infections because of age, several comorbidities or immunosuppression. Although many large clinical trials have shown the vaccine to be effective, the results of other studies raise questions regarding the immunogenicity of the vaccine in certain at risk populations 2, 3. Recent large trials and meta-analyses show a protection from invasive pneumococcal disease; however, a protection from pneumococcal pneumonia and any other pneumonia could not be shown. In contrast, in a recent Cochrane Database systematic review 4 the PPV was not effective in preventing … ER -